PDE5A and cancer: For Stage III cancers, PDE5 inhibitor exposure was associated with significantly improved OS at all timepoints compared with controls (1-year OS 96.4% vs 92.9%, p=0.05; 3‐year OS 91.7% vs 82.0%, p=0.001; 5‐year OS 88.3% vs 71.4%, p<0.001; HR, 0.40 [95% CI, 0.26–0.60]; Figure 1).